Global Oncology Drugs Market 2018-2024 - Drivers, Restraints, Opportunities, Trends, and Forecasts - ResearchAndMarkets.com

DUBLIN--()--The "Global Oncology Drugs Market 2018-2024" report has been added to ResearchAndMarkets.com's offering.

The global oncology drugs market is estimated to witness a CAGR of 7.0% during the forecast period 2018-2024. The market is analyzed based on three segments: therapeutic modality, applications, and regions.

The global oncology drugs market by therapeutic modality is segmented into chemotherapy, immunotherapy, targeted therapy, and others. Chemotherapy occupied the largest share in 2017, and immunotherapy is expected to grow at a high CAGR in the coming years due to high efficiency, increased preference of targeted immunotherapy from chemotherapy, and fewer side effects.

The global oncology drugs market by applications is segmented into breast cancer, blood cancer, prostate cancer, gastrointestinal cancer, lung cancer, and others. Blood cancer occupied the largest share in 2017, and lung cancer application is expected to be the fastest growing segment during the forecast period due to the high incidence of lung cancer and promising pipeline for NSCLC drugs.

The high adoption of personalized medicine and immuno-oncology have fueled a shift in cancer treatment from chemotherapy in the past decade. During 2011-2017, around 84 new drugs have been approved across 22 indications globally, of which immuno-oncology PD-1 and PD-L1 inhibitors have seen a speedy uptake based on their notable clinical profile and approval for various cancers.

Additionally, there is a robust late-stage oncology pipeline with around 630 unique molecules in the development, i.e., more than 7% when compared to the previous year, including 278 biological therapies and 82 vaccines. The market is dominated by key vendors such as F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb, Novartis AG, Celgene Corporation, Pfizer Inc., and Johnson & Johnson; and products of these firms are available globally through their distributors and subsidiaries.

Key Stakeholders:

Key Topics Covered:

1 Industry Outlook

2 Report Outline

3 Market Snapshot

4 Market Outlook

5 Market Characteristics

6 Therapeutic Modality: Market Size And Analysis

7 Application: Market Size And Analysis

8 Regions: Market Size And Analysis

9 Competitive Landscape

10 Vendor Profiles

  • F.Hoffmann-La Roche Ltd
  • Novartis AG
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Johnson & Johnson
  • Pfizer Inc.

11 Companies To Watch For

  • Astra Zenca Plc
  • Eli Lilly And Company.
  • Glaxosmithkline Plc
  • Merck & Co.
  • Sanofi
  • Amgen Inc.
  • Abbvie, Inc.


For more information about this report visit https://www.researchandmarkets.com/research/ns3cml/global_oncology?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs